Carlos A. Toro, PhD
Dr. Toro earned his Licentiate in Biochemistry from the University of Concepción, and his PhD in Molecular and Cellular Biology from the Austral University of Chile. He completed NIH-supported postdoctoral fellowships at Oregon Health & Science University, where he investigated the epigenetic regulation of neuroendocrine systems before shifting his focus to neuroplasticity, neuroinflammation, and repair following central nervous system trauma.
His current research aims to elucidate molecular mechanisms that drive functional recovery after spinal cord injury, with emphasis on connexin hemichannel modulation, neuroinflammatory signaling, and neuronal regeneration. He has developed transgenic SCI models, conducted transcriptomic and single-cell RNA sequencing studies, and advanced the preclinical development of boldine—a naturally derived connexin hemichannel blocker—as a potential therapeutic. His research focus employs advanced molecular tools, next-generation sequencing, and high-resolution imaging to address these questions.
Dr. Toro is an inventor on U.S. patents for the therapeutic use of boldine in nervous system injuries, recipient of the NIH/NIA Award for Professional Development, Co-Principal Investigator on a Department of Defense Spinal Cord Injury Research Program grant, and Principal Investigator on a New York State Spinal Cord Injury Research Board award. Across his roles at the VA, Mount Sinai, and BVMRF, Dr. Toro integrates scientific innovation with research leadership to translate laboratory discoveries into therapies that improve outcomes for Veterans and others living with spinal cord and brain injuries.